-
Ambulatory oxygen probably should not be routinely prescribed for patients with COPD who do not have a stable, resting arterial PaO2 less than 55 mm Hg.
-
A second, orally active, endothelin receptor (ET) antagonist has been approved for the treatment of pulmonary arterial hypertension.
-
Your next patient is a young mother of three who is looking for long-term, effective contraception. She says she is not ready to consider tubal sterilization. What methods can you offer her?
-
Your next patient says she is interested in using Lybrel, the new continuous-use oral contraceptive (OC). What should you tell her about this form of birth control?
-
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV.
-
If your practice includes older women, what is your approach in discussing risks for HIV? It's time to address such issues. Results of a new study indicate that older women may not be interested in being tested for HIV, despite having significant risk factors for lifetime exposure.
-
New research released on Lybrel, the first dedicated continuous use oral contraceptive (OC) (Wyeth Pharmaceuticals; Collegeville, PA), underscores the safety of the new drug.
-
How many women in your family planning facility may be missing a needed Pap smear? Check your numbers: One-fourth of uninsured U.S. women between the ages of 18-64 report not having had a Pap smear within the last three years of a government-issued survey.
-
With findings suggesting that male circumcision reduces risk of HIV acquisition for men, researchers now are turning attention on circumcision's impact on acquisition of sexually transmitted disease (STD) for women.
-
Does Chocolate Make Acne Worse?; Psoriasis Goes More Than Skin Deep; Riding the Chromium Pendulum; Size Matters Sometimes; Peripheral Arterial Disease and Antithrombotic Therapy: Sometimes Less is More; Osteoporosis in Men: Cost-effectiveness Issues
